

# Migraine Drugs Market to Grow at a CAGR of 4.56% to 2020

WiseGuyReports.com adds "Global Migraine Drugs Market 2016-2020" new report to its research database. The report Spread across 63 pages with tables and figures.

PUNE, INDIA, May 17, 2016 /EINPresswire.com/
-- The research analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020. A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

Complete Report Details Available at <a href="https://www.wiseguyreports.com/reports/global-migraine-drugs-market-2016-2020-migraine-drugs-market-2016-2020">https://www.wiseguyreports.com/reports/global-migraine-drugs-market-2016-2020</a>.



The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

## Key vendors

- Allergan
- Endo International
- GlaxoSmithKline

- Impax
- Pfizer

## Other prominent vendors

- Abbott
- Aegis Therapeutics
- Aeriel BioPharma
- Alder Biopharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Bayer
- CoLucid
- Dr. Reddy's Laboratories
- Eisai
- Eli Lilly
- Ethypharm
- IntelGenx
- Johnson & Johnson
- Klaria
- Kowa Pharmaceuticals America
- Luitpold Pharmaceuticals
- Meda
- Merck
- OptiNose
- Pfizer
- Pozen
- Raptor
- RedHill
- SUDA
- Teva
- TG Therapeutics
- NValeant
- Winston Pharmaceuticals
- Zogenix

# Order a 1-User License Report Copy @

https://www.wiseguyreports.com/checkout?currency=one\_user-USD&report\_id=466191.

### List of Exhibits

Exhibit 01: Product offerings

Exhibit 02: Percentage of migraine sufferers worldwide by gender

Exhibit 03: Global migraine drugs market: Pipeline portfolio

Exhibit 04: Global migraine drugs market 2015-2020 (\$ billions)

Exhibit 05: Five forces analysis

Exhibit 06: Preventative medications based on efficacy of drugs

Exhibit 07: Medications used based on severity of migraines

Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015

Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015

Exhibit 10: Market share of triptans by ROA 2015

Exhibit 11: Global migraine drugs market by geography 2015

Exhibit 12: Global migraine drugs market by geography 2015-2020 (\$ millions)

Exhibit 13: Migraine drugs market in Americas 2015-2020 (\$ billions)

Exhibit 14: Migraine drugs market in EMEA 2015-2020 (\$ millions)

Exhibit 15: Migraine drugs market in APAC 2015-2020 (\$ millions)

Exhibit 16: Impact of drivers

Exhibit 17: Percentage of population diagnosed with migraine in US 2014

Exhibit 18: Impact of drivers and challenges

Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 (\$ millions)

Exhibit 20: Allergan: Key takeaways

Exhibit 21: Endo International: Key takeaways

Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 (\$ millions)

Exhibit 23: GlaxoSmithKline: Key takeaways

Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 (\$ millions)

Exhibit 25: Impax: Key takeaways

Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 (\$ millions)

Exhibit 27: Pfizer: Key takeaways

Inquire more about this report at <a href="https://www.wiseguyreports.com/enquiry/global-migraine-drugs-market-2016-2020-migraine-drugs-market-2016-2020">https://www.wiseguyreports.com/enquiry/global-migraine-drugs-market-2016-2020</a>.

Norah Trent WiseGuy Research Consultants Pvt. Ltd. 16468459349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.